Heat Biologics Inc (NASDAQ:HTBX) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 524,800 shares, a growth of 43.2% from the July 31st total of 366,600 shares. Based on an average daily volume of 340,900 shares, the short-interest ratio is currently 1.5 days. Approximately 1.6% of the company’s stock are short sold.
Shares of HTBX traded up $0.02 during midday trading on Friday, reaching $0.58. 16,012 shares of the stock were exchanged, compared to its average volume of 415,622. Heat Biologics has a 12-month low of $0.46 and a 12-month high of $2.24. The firm has a 50 day simple moving average of $0.57 and a 200-day simple moving average of $0.87. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.01. The company has a market cap of $19.66 million, a price-to-earnings ratio of -0.64 and a beta of 1.75.
Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01. Heat Biologics had a negative return on equity of 75.51% and a negative net margin of 386.16%. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.91 million. Research analysts expect that Heat Biologics will post -0.65 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. increased its stake in shares of Heat Biologics Inc (NASDAQ:HTBX) by 6.8% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,327,660 shares of the biopharmaceutical company’s stock after acquiring an additional 84,400 shares during the period. Vanguard Group Inc. owned 3.90% of Heat Biologics worth $909,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.56% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. Alliance Global Partners set a $6.00 price target on Heat Biologics and gave the stock a “buy” rating in a research note on Friday, May 17th. Brookline Capital Management assumed coverage on Heat Biologics in a research note on Monday, July 29th. They set a “buy” rating and a $8.00 price target for the company.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.